- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.4: 11 residues within 4Å:- Chain A: S.179, E.181, P.182, N.232, F.345, N.346, C.347, G.348, V.414, S.415
- Ligands: NAG.32
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:G.348, A:V.414
NAG-NAG-BMA-MAN-MAN-MAN.13: 11 residues within 4Å:- Chain C: S.179, E.181, P.182, N.232, F.345, N.346, C.347, G.348, V.414, S.415
- Ligands: NAG.43
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:G.348, C:V.414
NAG-NAG-BMA-MAN-MAN-MAN.22: 11 residues within 4Å:- Chain E: S.179, E.181, P.182, N.232, F.345, N.346, C.347, G.348, V.414, S.415
- Ligands: NAG.54
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:G.348, E:V.414
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.5: 5 residues within 4Å:- Chain A: V.104, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:Y.135
NAG-NAG-BMA.6: 2 residues within 4Å:- Chain A: N.103, G.114
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.14: 5 residues within 4Å:- Chain C: V.104, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain C- Hydrophobic interactions: C:Y.135
NAG-NAG-BMA.15: 2 residues within 4Å:- Chain C: N.103, G.114
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.23: 5 residues within 4Å:- Chain E: V.104, N.118, Y.135, L.137, D.290
1 PLIP interactions:1 interactions with chain E- Hydrophobic interactions: E:Y.135
NAG-NAG-BMA.24: 2 residues within 4Å:- Chain E: N.103, G.114
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-FUC.7: 4 residues within 4Å:- Chain A: N.106, N.107, G.293, D.294
No protein-ligand interaction detected (PLIP)NAG-NAG-FUC.16: 4 residues within 4Å:- Chain C: N.106, N.107, G.293, D.294
No protein-ligand interaction detected (PLIP)NAG-NAG-FUC.25: 4 residues within 4Å:- Chain E: N.106, N.107, G.293, D.294
No protein-ligand interaction detected (PLIP)- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-FUC.9: 6 residues within 4Å:- Chain B: P.98, W.99, N.100, S.102, W.103, Y.127
1 PLIP interactions:1 interactions with chain B- Hydrophobic interactions: B:P.98, B:Y.127
NAG-FUC.18: 6 residues within 4Å:- Chain D: P.98, W.99, N.100, S.102, W.103, Y.127
1 PLIP interactions:1 interactions with chain D- Hydrophobic interactions: D:P.98, D:Y.127
NAG-FUC.27: 6 residues within 4Å:- Chain F: P.98, W.99, N.100, S.102, W.103, Y.127
1 PLIP interactions:1 interactions with chain F- Hydrophobic interactions: F:P.98, F:Y.127
- 33 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.28: 2 residues within 4Å:- Chain A: N.204, T.206
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain A: N.361
- Ligands: NAG-NAG.3
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: N.308, T.363
Ligand excluded by PLIPNAG.31: 6 residues within 4Å:- Chain A: Q.263, N.265, N.301, V.302, S.303, R.412
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: V.414, S.415, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.4
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain A: N.271, I.292, V.410
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain A: S.120, F.121, N.122
Ligand excluded by PLIPNAG.35: 4 residues within 4Å:- Chain A: R.162, N.167, T.168
- Chain C: R.278
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain A: N.324
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain B: N.107, S.109, E.110
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain B: K.122, E.123, N.126, Y.127
Ligand excluded by PLIPNAG.39: 2 residues within 4Å:- Chain C: N.204, T.206
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain C: N.361
- Ligands: NAG-NAG.12
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: N.308, T.363
Ligand excluded by PLIPNAG.42: 6 residues within 4Å:- Chain C: Q.263, N.265, N.301, V.302, S.303, R.412
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain C: V.414, S.415, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.13
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain C: N.271, I.292, V.410
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain C: S.120, F.121, N.122
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain C: R.162, N.167, T.168
- Chain E: R.278
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain C: N.324
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain D: N.107, S.109, E.110
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain D: K.122, E.123, N.126, Y.127
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain E: N.204, T.206
Ligand excluded by PLIPNAG.51: 2 residues within 4Å:- Chain E: N.361
- Ligands: NAG-NAG.21
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain E: N.308, T.363
Ligand excluded by PLIPNAG.53: 6 residues within 4Å:- Chain E: Q.263, N.265, N.301, V.302, S.303, R.412
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain E: V.414, S.415, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.22
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain E: N.271, I.292, V.410
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain E: S.120, F.121, N.122
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain A: R.278
- Chain E: R.162, N.167, T.168
Ligand excluded by PLIPNAG.58: 1 residues within 4Å:- Chain E: N.324
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain F: N.107, S.109, E.110
Ligand excluded by PLIPNAG.60: 4 residues within 4Å:- Chain F: K.122, E.123, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nogal, B. et al., Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell Rep (2020)
- Release Date
- 2020-04-01
- Peptides
- BG505 SOSIPv5.2 gp120: ACE
BG505 SOSIPv5.2 gp41: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
DB
BD
EF
F
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- FUC: alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 33 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Nogal, B. et al., Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell Rep (2020)
- Release Date
- 2020-04-01
- Peptides
- BG505 SOSIPv5.2 gp120: ACE
BG505 SOSIPv5.2 gp41: BDF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
DB
BD
EF
F